What are the pharmacological effects and therapeutic mechanisms of Revumenib?

Revumenib (R&D code: SNDX-5613) is a new type of targeted oral small molecule drug. Its core pharmacological mechanism is to selectively inhibit the Menin-KMT2A (formerly MLL) protein interaction, thereby blocking the pathogenic pathways of specific types of leukemia. This medicine is made bySyndax Developed by Pharmaceuticals, it is mainly used to treat patients with KMT2A rearrangement (KMT2Ar) or NPM1 mutations have shown significant efficacy in patients with relapsed or refractory acute leukemia, especially in acute myeloid leukemia (AML). It has strong target specificity and novel mechanism of action, and has received widespread attention in the field of hematological tumors in recent years.

Under normal physiological conditions, Menin is a protein involved in the regulation of various cell signals. However, in KMT2A rearrangement (KMT2Ar) leukemia, Menin will interact withMenin span>KMT2Afusion proteins (such asKMT2A-AF4) form abnormal protein complexes, activate HOXA9, MEIS1 and other leukemia-related genes, drive the unlimited proliferation of leukemia cells and prevent differentiation. Revemenib inhibits the binding between Menin and KMT2A fusion proteins, interrupts this carcinogenic mechanism, causes leukemia cells to differentiate and undergo apoptosis, thereby exerting anti-tumor effects.

In addition to KMT2Arleukemia, revimenib also has potential efficacy against NPM1mutatedAML. NPM1 mutations activate the expression of the HOX gene cluster through a similar mechanism, and the Menin protein also plays a supporting role in this process. Therefore, Revimenib can also inhibit this pathway and achieve the therapeutic effect on NPM1 mutant AML. Early clinical studies (e.g.The AUGMENT-101 trial) showed that revimenib can induce durable responses in these patient groups, and some patients achieved minimal residual disease (MRD) negative status.

In general, Revimenib is a precise treatment drug that targets the carcinogenesis mechanism at the molecular level. It does not rely on traditional cytotoxic chemotherapy. It has the advantages of clear target, significant efficacy, and relatively mild side effects. As the first breakthrough product in the field of Menin inhibitors, Revimenib is promoting the transformation of leukemia treatment from "pan-chemotherapy" to "personalized targeted therapy", providing new treatment options for high-risk leukemia patients with specific genetic abnormalities. In the future, the drug may also be combined with FLT3 inhibitors, BCL-2 inhibitors, etc. to expand a wider range of indications and improve therapeutic effects.

Reference materials:https://www.drugs.com/